Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting
The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting. This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2017-03, Vol.37 (3), p.1507-1514 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1514 |
|---|---|
| container_issue | 3 |
| container_start_page | 1507 |
| container_title | Anticancer research |
| container_volume | 37 |
| creator | Yoh, Kiyotaka Goto, Yasushi Naito, Yoichi Kishi, Kazuma Mori, Kiyoshi Hotta, Katsuyuki Hosomi, Yukio Yamada, Kazuhiko Tanai, Chiharu Tomizawa, Yoshio Inoue, Akira Hasegawa, Yoshinori Nishio, Makoto Ohashi, Yasuo Kunitoh, Hideo |
| description | The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.
This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up.
Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy.
Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy. |
| doi_str_mv | 10.21873/anticanres.11478 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1878819035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1878819035</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-8df338d411f7c7006670da6b2c52010085a3e200d05b4b67cc1787da071e06473</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EoqXwAWyQl2xSxnESu0sU8ahUHoKyjiaO0wYlTrAdVf170lJgM7O55-rqEHLJYBoyKfgNGl8pNFa7KWORkEdkzMSMBSLmcEzGEMYQCIB4RM6c-wRIkpnkp2QUSs4iHiZjks-bDpWnbUmfsDJeGzRK0-VaW-y2tGwtfUVfaeMd3VR-TZ9bE7gG65qmejiL3qxoumMsrQxF-qaxDjatrQv6rr2vzOqcnJRYO31x-BPycX-3TB-DxcvDPL1dBIpHkQ9kUXIui4ixUiix2yqgwCQPVRwCA5Axch0CFBDnUZ4IpZiQokAQTEMSCT4h1z-9nW2_eu181lRODSPR6LZ32WBMSjYDHg9R9hNVtnXO6jLrbNWg3WYMsr3a7F9ttlc7MFeH-j5vdPFH_Lrk39cgdhc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1878819035</pqid></control><display><type>article</type><title>Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yoh, Kiyotaka ; Goto, Yasushi ; Naito, Yoichi ; Kishi, Kazuma ; Mori, Kiyoshi ; Hotta, Katsuyuki ; Hosomi, Yukio ; Yamada, Kazuhiko ; Tanai, Chiharu ; Tomizawa, Yoshio ; Inoue, Akira ; Hasegawa, Yoshinori ; Nishio, Makoto ; Ohashi, Yasuo ; Kunitoh, Hideo</creator><creatorcontrib>Yoh, Kiyotaka ; Goto, Yasushi ; Naito, Yoichi ; Kishi, Kazuma ; Mori, Kiyoshi ; Hotta, Katsuyuki ; Hosomi, Yukio ; Yamada, Kazuhiko ; Tanai, Chiharu ; Tomizawa, Yoshio ; Inoue, Akira ; Hasegawa, Yoshinori ; Nishio, Makoto ; Ohashi, Yasuo ; Kunitoh, Hideo</creatorcontrib><description>The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.
This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up.
Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy.
Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.11478</identifier><identifier>PMID: 28314326</identifier><language>eng</language><publisher>Greece</publisher><subject><![CDATA[Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab - administration & dosage ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Cisplatin - administration & dosage ; Disease Progression ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Male ; Middle Aged ; Multivariate Analysis ; Organoplatinum Compounds - administration & dosage ; Paclitaxel - administration & dosage ; Pemetrexed - administration & dosage ; Prospective Studies ; Research Design ; Treatment Outcome]]></subject><ispartof>Anticancer research, 2017-03, Vol.37 (3), p.1507-1514</ispartof><rights>Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-8df338d411f7c7006670da6b2c52010085a3e200d05b4b67cc1787da071e06473</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28314326$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoh, Kiyotaka</creatorcontrib><creatorcontrib>Goto, Yasushi</creatorcontrib><creatorcontrib>Naito, Yoichi</creatorcontrib><creatorcontrib>Kishi, Kazuma</creatorcontrib><creatorcontrib>Mori, Kiyoshi</creatorcontrib><creatorcontrib>Hotta, Katsuyuki</creatorcontrib><creatorcontrib>Hosomi, Yukio</creatorcontrib><creatorcontrib>Yamada, Kazuhiko</creatorcontrib><creatorcontrib>Tanai, Chiharu</creatorcontrib><creatorcontrib>Tomizawa, Yoshio</creatorcontrib><creatorcontrib>Inoue, Akira</creatorcontrib><creatorcontrib>Hasegawa, Yoshinori</creatorcontrib><creatorcontrib>Nishio, Makoto</creatorcontrib><creatorcontrib>Ohashi, Yasuo</creatorcontrib><creatorcontrib>Kunitoh, Hideo</creatorcontrib><title>Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.
This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up.
Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy.
Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab - administration & dosage</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Cisplatin - administration & dosage</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Paclitaxel - administration & dosage</subject><subject>Pemetrexed - administration & dosage</subject><subject>Prospective Studies</subject><subject>Research Design</subject><subject>Treatment Outcome</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRS0EoqXwAWyQl2xSxnESu0sU8ahUHoKyjiaO0wYlTrAdVf170lJgM7O55-rqEHLJYBoyKfgNGl8pNFa7KWORkEdkzMSMBSLmcEzGEMYQCIB4RM6c-wRIkpnkp2QUSs4iHiZjks-bDpWnbUmfsDJeGzRK0-VaW-y2tGwtfUVfaeMd3VR-TZ9bE7gG65qmejiL3qxoumMsrQxF-qaxDjatrQv6rr2vzOqcnJRYO31x-BPycX-3TB-DxcvDPL1dBIpHkQ9kUXIui4ixUiix2yqgwCQPVRwCA5Axch0CFBDnUZ4IpZiQokAQTEMSCT4h1z-9nW2_eu181lRODSPR6LZ32WBMSjYDHg9R9hNVtnXO6jLrbNWg3WYMsr3a7F9ttlc7MFeH-j5vdPFH_Lrk39cgdhc</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Yoh, Kiyotaka</creator><creator>Goto, Yasushi</creator><creator>Naito, Yoichi</creator><creator>Kishi, Kazuma</creator><creator>Mori, Kiyoshi</creator><creator>Hotta, Katsuyuki</creator><creator>Hosomi, Yukio</creator><creator>Yamada, Kazuhiko</creator><creator>Tanai, Chiharu</creator><creator>Tomizawa, Yoshio</creator><creator>Inoue, Akira</creator><creator>Hasegawa, Yoshinori</creator><creator>Nishio, Makoto</creator><creator>Ohashi, Yasuo</creator><creator>Kunitoh, Hideo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170301</creationdate><title>Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting</title><author>Yoh, Kiyotaka ; Goto, Yasushi ; Naito, Yoichi ; Kishi, Kazuma ; Mori, Kiyoshi ; Hotta, Katsuyuki ; Hosomi, Yukio ; Yamada, Kazuhiko ; Tanai, Chiharu ; Tomizawa, Yoshio ; Inoue, Akira ; Hasegawa, Yoshinori ; Nishio, Makoto ; Ohashi, Yasuo ; Kunitoh, Hideo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-8df338d411f7c7006670da6b2c52010085a3e200d05b4b67cc1787da071e06473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab - administration & dosage</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Cisplatin - administration & dosage</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Paclitaxel - administration & dosage</topic><topic>Pemetrexed - administration & dosage</topic><topic>Prospective Studies</topic><topic>Research Design</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoh, Kiyotaka</creatorcontrib><creatorcontrib>Goto, Yasushi</creatorcontrib><creatorcontrib>Naito, Yoichi</creatorcontrib><creatorcontrib>Kishi, Kazuma</creatorcontrib><creatorcontrib>Mori, Kiyoshi</creatorcontrib><creatorcontrib>Hotta, Katsuyuki</creatorcontrib><creatorcontrib>Hosomi, Yukio</creatorcontrib><creatorcontrib>Yamada, Kazuhiko</creatorcontrib><creatorcontrib>Tanai, Chiharu</creatorcontrib><creatorcontrib>Tomizawa, Yoshio</creatorcontrib><creatorcontrib>Inoue, Akira</creatorcontrib><creatorcontrib>Hasegawa, Yoshinori</creatorcontrib><creatorcontrib>Nishio, Makoto</creatorcontrib><creatorcontrib>Ohashi, Yasuo</creatorcontrib><creatorcontrib>Kunitoh, Hideo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoh, Kiyotaka</au><au>Goto, Yasushi</au><au>Naito, Yoichi</au><au>Kishi, Kazuma</au><au>Mori, Kiyoshi</au><au>Hotta, Katsuyuki</au><au>Hosomi, Yukio</au><au>Yamada, Kazuhiko</au><au>Tanai, Chiharu</au><au>Tomizawa, Yoshio</au><au>Inoue, Akira</au><au>Hasegawa, Yoshinori</au><au>Nishio, Makoto</au><au>Ohashi, Yasuo</au><au>Kunitoh, Hideo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>37</volume><issue>3</issue><spage>1507</spage><epage>1514</epage><pages>1507-1514</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.
This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up.
Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy.
Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.</abstract><cop>Greece</cop><pmid>28314326</pmid><doi>10.21873/anticanres.11478</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2017-03, Vol.37 (3), p.1507-1514 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1878819035 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Cisplatin - administration & dosage Disease Progression Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Middle Aged Multivariate Analysis Organoplatinum Compounds - administration & dosage Paclitaxel - administration & dosage Pemetrexed - administration & dosage Prospective Studies Research Design Treatment Outcome |
| title | Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Maintenance%20Therapy%20for%20Patients%20with%20Non-small%20Cell%20Lung%20Cancer%20in%20a%20Real-world%20Setting&rft.jtitle=Anticancer%20research&rft.au=Yoh,%20Kiyotaka&rft.date=2017-03-01&rft.volume=37&rft.issue=3&rft.spage=1507&rft.epage=1514&rft.pages=1507-1514&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.11478&rft_dat=%3Cproquest_cross%3E1878819035%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1878819035&rft_id=info:pmid/28314326&rfr_iscdi=true |